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Summary
Antibody 7A1 hydrolyzes cocaine to produce nonpsy-
choactive metabolites ecgonine methyl ester and ben-
zoic acid. Crystal structures of 7A1 Fab0 and six com-
plexes with substrate cocaine, the transition state
analog, products ecgonine methyl ester and benzoic
acid together and individually, as well as heptaethyl-
ene glycol have been analyzed at 1.5–2.3 A˚ resolution.
Here, we present snapshots of the complete cycle of
the cocaine hydrolytic reaction at atomic resolution.
Significant structural rearrangements occur along
the reaction pathway, but they are generally limited
to the binding site, including the ligands themselves.
Several interacting side chains either change their ro-
tamers or alter their mobility to accommodate the dif-
ferent reaction steps. CDR loop movements (up to
2.3 A˚) and substantial side chain rearrangements (up
to 9 A˚) alter the shape and size (w320–500 A˚3) of the
antibody active site from ‘‘open’’ to ‘‘closed’’ to ‘‘open’’
for the substrate, transition state, and product states,
respectively.
Introduction
Abuse of cocaine is a major public health concern and
has been a significant societal problem (SAMHSA,
2004). Despite intensive multidisciplinary research, no
effective treatments approved by the Food and Drug Ad-
ministration (FDA) are available for cocaine craving, ad-
diction, and overdose. The development of effective
therapies for cocaine abuse has been frustrated by the
difficulties inherent in inhibiting a blocking agent, since
cocaine acts as an indirect dopamine agonist to block
the dopamine transporter in the pleasure center of the
brain. Nevertheless, a number of medications show
some promise (Sofuoglu and Kosten, 2005). Immuno-
pharmacotherapy has been proposed based on periph-
eral blockade rather than central blockade, in which an-
tibodies are used to neutralize the drug, as a promising
means to treat cocaine abuse (Carrera et al., 1995, 2000;
Fox et al., 1996). Antibodies would intercept cocaine in
the peripheral circulation before it is partitioned into
*Correspondence: kdjanda@scripps.edu (K.D.J.); wilson@scripps.
edu (I.A.W.)the central nervous system, since the drug must pass
through the blood to reach the brain.
Cocaine binding antibodies have shown promising ef-
fects to neutralize cocaine toxicity (Carrera et al., 2000);
however, a limitation of the utility of cocaine binding an-
tibodies is the 1:1 binding stoichiometry that would be
saturated by larger doses of cocaine, whereas a catalytic
antibody would be regenerated with each turnover. Ad-
ministration of a monoclonal antibody (mAb) endowed
not only with high binding affinity, but also with catalytic
activity to metabolize cocaine, would have enhanced
therapeutic effects if the kinetic properties of the anti-
body were appropriate (Matsushita et al., 2001).
Ester hydrolysis has been one of the hallmark reac-
tions catalyzed by antibodies (Tanaka, 2002). Murine
catalytic antibody 7A1 was elicited against a phos-
phonate mono-ester transition state analog (TSA) of co-
caine 5 (GNL) (Figure 1) coupled through a covalent link-
age to the carrier protein keyhole limpet hemocyanin
(KLH) (Matsushita et al., 2001). Antibody 7A1 hydrolyzes
the benzoyl ester of cocaine 1 to yield the nonpsychoac-
tive metabolites ecgonine methyl ester 3 and benzoic
acid 4 (Figure 1; Table 1). The potential therapeutic ap-
plication for cocaine catalytic antibodies would be en-
hanced by improved kinetic parameters, manifested ei-
ther by a lower KM and/or by a greater kcat. Thus,
structural studies were initiated to determine the molec-
ular basis for catalysis and to reveal possible mutations
that could increase catalytic proficiency, as well as pro-
vide a foundation for the humanization of the murine an-
tibody to facilitate human clinical trials.
Ideally, catalytic mechanistic studies should include
experimentally determined structures of all steps along
the reaction pathway, but that is rarely possible in prac-
tice. However, 7A1 Fab0 was amenable to cocrystalliza-
tion with substrate, a transition state analog, and both
products that enabled crystal structures of antibody 7A1
Fab0 as well as five complexes to be determined for the
major steps along the reaction coordinate: the apo form,
and complexs with substrate cocaine 1, TSA 6, both
products (ecgonine methyl ester 3 and benzoate 4),
product ecgonine methyl ester 3, and, finally, the other
product, benzoate 4 (Table 2). 7A1 Fab0 in the heptaeth-
ylene glycol complex was also determined (Table 2)
to probe antibody conformational flexibility. Here, we
present snapshots of the complete cycle of the cocaine
antibody catalytic reaction at atomic resolution.
Results
Activity Assay of Antibody 7A1
The kinetic parameters KM, kcat, and kuncat for the hydro-
lysis of substrate cocaine 1 by mAb 7A1 were deter-
mined in three different buffer systems: 100 mM phos-
phate buffer (pH 7.4) with a KM of 0.75 mM, a kcat of
0.025 min21, and a kuncat of 9.37 3 10
26 min21; 100 mM
bicine buffer (pH 8.0) with a KM of 3.47 mM, a kcat
of 0.087 min21, and a kuncat of 2.93 3 10
25 min21; and
100 mM MOPS buffer (pH 7.4) with a KM of 2.77 mM,
a kcat of 0.035 min
21, and a kuncat of 7.65 3 10
26 min21
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206Figure 1. Antibody-Catalyzed Hydrolysis of
Cocaine
Antibody 7A1 hydrolyzes cocaine 1 to give
products ecgonine methyl ester 3 and ben-
zoic acid 4 through transition state 2. Hapten
GNL 5 was used to elicit antibody 7A1, while
transition state analog 6 was used in crystal-
lization with 7A1 Fab0.(Table 1). At measured pH values of 6.4, 7.1, 7.4, 8.0, and
8.5, the Vmax of antibody 7A1 increased linearly with pH,
with no rate enhancement over uncatalyzed rates below
pH 6.4. Kinetic assays revealed no product inhibition in
reactions containing benzoic acid up to concentrations
of 10 mM, while slight inhibition was observed with ecgo-
nine methyl ester at high concentrations (IC50z 5 mM).
Further, no inhibition of catalysis by heptaethylene gly-
col was detected up to 1 mM concentration. All of the ex-
periments were performed three times, and the error bar
for the measured KM and kcat values were less than or
equal to 5% of the reported values.
Overview of the Crystal Structures
Seven structures of 7A1 Fab0 were determined at me-
dium to high resolution (Table 2) in the apo form (1.5 A˚)
and as complexes with six ligands: substrate cocaine
(1.5 A˚); the transition state analog (1.85 A˚); two products,
ecgonine methyl ester and benzoic acid (2.1 A˚); product
ecgonine methyl ester (2.3 A˚); product benzoic acid
(1.85 A˚); as well as heptaethylene glycol (1.70 A˚). 7A1
Fab0 has an immunoglobulin (Ig) g1 heavy chain (H) and
a k light chain (L) (Figure 2). Electron density maps for
all 7A1 Fab0 structures are of high quality, except for
a flexible loop (residues 127–135) in the CH1 domain,
which usually has poor to no electron density in almost
all Fab crystal structures (Zhu et al., 2003). The elbow an-
gles between the variable and constant domains of the
Fab molecules are 141.9º (apo form), 141.8º (substrate
complex), 134.1º (TSA complex), 136.0º (two-product
complex), 139.6º and 138.7º (ecgonine methyl ester
complex for molecules 1 and 2, respectively), 135.1º
(benzoic acid complex), and 138.0º (heptaethylene gly-
col complex). The six complementarity-determining re-
gions (CDRs) from the light (L1, L2, L3) and heavy (H1,
Table 1. Kinetic Parameters for Antibody 7A1-Catalyzed Cocaine
Hydrolysis
Buffer
100 mM PB
(pH 7.4)
100 mM Bicine
(pH 8.0)
100 mM MOPS
(pH 7.4)
KM (mM) 0.75 3.47 2.77
kcat (min
21) 0.025 0.087 0.035
kuncat (min
21) 9.37 3 1026 2.93 3 1025 7.65 3 1026
kcat/kuncat 2.63 3 10
3 2.98 3 103 4.63 3 103H2, H3) chains that form the antibody-combining site
have well-defined electron density and adopt known
canonical conformations. CDR L3 resembles canonical
structure 1 (Al-Lazikani et al., 1997) in the two-product
complex, but, in the other structures, the backbone f,
c values of L95, L96, or L97 in CDR L3 deviate signifi-
cantly from canonical mean values by 50º–100º. The
torso of CDR H3 contains the characteristic b bulge at
AspH101 (Morea et al., 1998), but the usual salt bridge
between ArgH94 and AspH101 is not made due to steric
block by TyrH102.
Architecture of the Antigen Binding Pocket
The bound ligands are all clearly visible in the electron
density maps (Figure 3), allowing unequivocal identifica-
tion of the catalytic pocket and the Fab-ligand interac-
tions. The binding pocket is generally made up of aro-
matic residues; PheL91 (L3), PheL96 (L3), and AlaH34
(H1) constitute the floor of the pocket, while TyrL27D
(L1), TyrL94 (L3), TyrH50 (H2), ArgH52 (H2), and TyrH97
(H3), as well as the main chain of ValL92 (L3) and
GluL93 (L3), form the sides (Figure 3). The combining site
pocket is a shallow groove rather than the deep pocket
found in other esterolytic antibodies (Figures 3 and 4). In
the 7A1 Fab0 apo structure at 1.5 A˚ (Figure 3A), the side
chains of TyrL94 and TyrH97 have weak electron den-
sity, indicative of conformational flexibility, but they
appear to be key for catalysis as suggested in the follow-
ing 7A1 Fab0 substrate, TSA, and product complex struc-
tures. As in other antibody-hapten complexes (Wilson
and Stanfield, 1993), CDR L2 does not contribute to
the antigen-antibody interaction.
Substrate Binding
It is not common to crystallize enzyme-substrate com-
plexes, but, in this case, a high concentration of cocaine
(w20:1 molar ratio of cocaine to antibody Fab0) at pH 5.5
reduces the antibody activity and enables cocrystalliza-
tion as a stable Michaelis-Menten complex (Figure 3B).
Clear, interpretable electron density was found for co-
caine in the active site with full occupancy, as reflected
by the B values of the cocaine ligand (24–32 A˚2), which
are comparable to nearby antibody residues (15–45 A˚2,
average 24 A˚2). The cocaine molecule is buried such
that the tropane moiety and the benzoate substituent
Snapshots of a Cocaine Antibody Catalytic Cycle
207Table 2. Data Collection and Refinement Statistics of 7A1 Fab0 Crystals
Data Set Native Cocaine
Transition
State Analog
Two
Productsa
Ecgonine
Methyl Ester
Benzoic
Acid
Heptaethylene
Glycol
Space group C2221 C2221 P21 C2221 P21 C2221 P43212
Unit cell (A˚) a = 89.8,
b = 117.3,
c = 86.0
a = 90.3,
b = 117.3,
c = 85.2
a = 47.7,
b = 73.7,
c = 73.4
a = 83.6,
b = 89.8,
c = 154.4
a = 47.9,
b = 78.5,
c = 130.3
a = 82.6,
b = 89.1,
c = 153.5
a = 88.1,
b = 88.1,
c = 135.4
Unit cell (º) b = 98.7 b = 91.9
Resolution (A˚)b 50.0–1.50
(1.55–1.50)
50.0–1.50
(1.54–1.50)
50.0–1.85
(1.92–1.85)
50.0–2.10
(2.15–2.10)
50.0–2.30
(2.38–2.30)
50.0–1.85
(1.89–1.85)
50.0–1.70
(1.76–1.70)
X-ray source ALS 8.3.1 ALS 8.2.1 ALS 5.0.2 ALS 8.3.1 ALS 5.0.2 ALS 8.2.2 SSRL 9-2
Unique refs 72,464 72,094 40,762 34,262 40,412 48,913 59,095
Redundancyb 4.0 (3.1) 4.0 (3.0) 3.1 (3.0) 3.5 (3.0) 2.9 (2.0) 4.0 (3.5) 6.0 (5.5)
Average I/s(I)b 35.4 (1.5) 41.6 (1.7) 24.0 (4.3) 23.8 (1.3) 20.3 (4.5) 31.7 (1.8) 36.2 (2.6)
Completenessb 99.5 (97.4) 99.5 (97.7) 94.7 (87.9) 99.3 (95.7) 90.2 (65.2) 99.6 (97.9) 99.8 (99.9)
Rsym
c 0.038 (0.613) 0.052 (0.660) 0.066 (0.266) 0.074 (0.743) 0.099 (0.363) 0.058 (0.571) 0.057 (0.787)
Molecules in a.u. 1 1 1 1 2 1 1
Vmax (A˚
3/Da) 2.4 2.3 2.7 3.0 2.6 2.9 2.7
Refined residues 435 435 435 435 870 435 435
Refined waters 486 439 457 175 263 332 405
Rcryst
d 0.181 0.182 0.227 0.225 0.238 0.217 0.209
Rfree
e 0.228 0.227 0.255 0.246 0.285 0.238 0.233
B values (A˚2)
Protein 26.7 26.9 21.0 46.0 35.4 40.0 28.9
Water 41.0 39.2 34.9 52.9 40.7 51.4 40.1
Ligands — 25.9 14.0 51.9 59.7 64.0 38.3
Ramachandran plot (%)f 90.2, 8.7,
0.5, 0.5
90.5, 8.4,
0.5, 0.5
90.2, 8.7,
0.5, 0.5
90.0, 9.0,
0.5, 0.5
88.9, 10.0,
0.8, 0.3
89.7, 9.5,
0.5, 0.3
90.0, 8.7,
0.8, 0.5
Rmsd bond (A˚) 0.014 0.013 0.007 0.007 0.009 0.007 0.010
Rmsd angle (º) 1.6 1.6 1.4 1.4 1.6 1.4 1.3
a The two products are ecgonine methyl ester and benzoic acid.
b Parentheses denote outer-shell statistics.
c Rsym =
P
h
P
i jIi (h) 2 <I(h)>j /
P
h
P
i Ii (h), where < I(h)> is the average intensity of i symmetry-related observations of reflections with Bragg
index h.
d Rcryst =
P
hkl jFo 2 Fcj /
P
hkl jFoj, where Fo and Fc are the observed and calculated structure factors, respectively.
e Rfree was calculated as for Rcryst, but on 5% of the data excluded before refinement.
f The values are a percentage of residues in the most favored, additional favored, generously allowed, and disallowed regions. MetL51, as
expected, shows main chain torsion angles in the disallowed regions, but in a well-defined g turn that is observed in most antibody structures
(Al-Lazikani et al., 1997). SerH54, clearly defined in the electron density maps, also exhibits unusual main chain torsion angles at the tip of a g turn.lie on the floor of the binding pocket, with the carbonyl
oxygen of the benzoyl ester pointing toward the outer
rim of the cleft (Figures 3B and 4B). The cocaine adopts
an energetically favorable chair conformation, and there
is an intramolecular hydrogen bond between the tro-pane nitrogen and the carbonyl oxygen of the methyl
ester, as observed in two cocaine binding antibodies
(Larsen et al., 2001; Pozharski et al., 2005). Interestingly,
this hydrogen bond is not observed in the small-
molecule crystal structures of cocaine-HCl or its freeFigure 2. Crystal Structure of the 7A1 Fab0
Cocaine Complex with the Ca Trace of the An-
tibody Light and Heavy Chains Colored in
Light and Dark Gray, Respectively
CDRs L1, L2, and L3 are colored brown, while
CDRs H1, H2, and H3 are colored blue. Sub-
strate cocaine is also shown with yellow car-
bons in the active site. All of the figures were
generated in Bobscript (Esnouf, 1999) and
rendered in Raster3D (Merritt and Murphy,
1994).
Figure 3. Stereoview of the Active Site of 7A1
Corresponding to Different Steps in the Reac-
tion Pathway
(A) Apo form (1.5 A˚).
(B) Complex with substrate cocaine (1.5 A˚).
(C) Complex with the transition state analog
(TSA) (1.85 A˚).
(D) Complex with both products, ecgonine
methyl ester and benzoate (2.1 A˚).
(E) Complex with product ecgonine methyl
ester (2.3 A˚).
(F) Complex with product benzoate (1.85 A˚).
Disordered side chains are highlighted in
dashed bonds. Alternate conformations of
TrpH47 and the partially occupied TyrL94
are rendered with pink side chains in the 7A1
Fab0 cocaine complex. The corresponding
ligands for each structure are shown with yel-
low carbons, blue nitrogens, red oxygens and
green phosphorus atoms. Water molecules in
the active site are shown in red spheres, and
the conserved water is labeled S1.
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209base, crack cocaine, from the Cambridge Structural
Database (Allen, 2002). Cocaine-HCl was used in the co-
crystallization, and the torsion angle around the methyl
ester carbonyl (among O5-C6-C8-C10) is rotated about
120º in its complex with 7A1 Fab0, as compared to its
small-molecule crystal structure. The tropane nitrogen
atom to methyl oxygen distance is then reduced from
4.1 A˚ to 2.8 A˚. The tropane nitrogen hydrogen in this in-
Figure 4. The Combining Site of 7A1 as It Changes Shape and Size
throughout the Reaction Cycle
(A–F) The binding site is shown as a molecular surface colored by
electrostatic potential (calculated with GRASP [Nicholls et al.,
1991] with a 1.4 A˚ probe radius and contoured between 230 and
+30 kT). The corresponding ligands are shown in ball-and-stick rep-
resentation with yellow carbons. (A) Apo form. (B) Complex with
substrate cocaine. (C) Complex with the transition state analog
(TSA). (D) Complex with both products, ecgonine methyl ester and
benzoate. (E) Complex with product ecgonine methyl ester. (F) Com-
plex with product benzoate.tramolecular hydrogen bond also forms a bifurcated hy-
drogen bond with the main chain carbonyl oxygen of
PheL91. Otherwise, the tropane and benzoate moieties
are superimposable, with no obvious substrate strain
on the cocaine molecule.
The cocaine molecule is 78% buried in the active site
pocket (Figure 4B) that exhibits high complementarity to
the ligand with a shape correlation parameter, Sc (Law-
rence and Colman, 1993), of 0.89 (Table 3). A total of 74
van der Waals’ interactions are made between the anti-
body and cocaine, 45 of which are derived from the light
chain (Table 3). The majority of 7A1 Fab0 contact resi-
dues are hydrophobic or aromatic, with the exception
of ArgH52. The tropane moiety contacts TyrL27D,
TyrL32, PheL91, ValL92, and TyrH97; the methyl ester in-
teracts with PheL91, ValL92, TyrL94, and PheL96; while
the benzoate substituent contacts AlaH34, TyrH50,
ArgH52, and PheL96. At physiological pH, the tertiary
amino group of cocaine (pKa w8.6) would be proton-
ated, affording a net positive charge. Interestingly, the
positively charged tropane nitrogen atom is centered
almost exactly over the aromatic ring of TyrL27D and
TyrL32, with distances of 4.6 and 4.3 A˚ between the
nitrogen atom and the centers of the aromatic rings;
these data are consistent with a cation-p interaction,
as found in many proteins (Dougherty, 1996).
The cocaine scissile benzoyl ester carbonyl carbon,
which should be the target of nucleophilic attack by
a general base or hydroxide ion, is distant (at least 6 A˚)
from any likely active site candidates, and the closest
water molecule is 3.9 A˚. Thus, the Fab0 in the cocaine
complex appears to be inactive or in a low activity form
at this pH, consistent with lack of cleavage of the co-
caine ligand. The apo antibody is also presumably in a
catalytically inactive state and is complementary to nei-
ther substrate nor transition state. As the apo 7A1 Fab0
and cocaine complex crystallize in the same conditions
with similar crystal packing, conformational changes
can be accurately assessed between these two crystal
structures. Both structures superimpose well, with an
rmsd for all Ca atoms of the Fv domain of 0.32 A˚, which
corresponds to the approximate experimental error
(w0.2 A˚). For the CDR loops, the largest, but still rela-
tively small, backbone differences are observed around
LeuL27C–TyrL32 (rmsd of Ca atoms of 0.6 A˚) of the
L1 loop and PheL91–ProL95 (rmsd of Ca atoms of
0.7 A˚) of L3, which slightly enlarge the combining site.
The most significant conformational changes occur
for TyrH97 and TyrL94 in the active site, which are flex-
ible in the apo form; however, in the cocaine com-
plex, TyrH97 is fully ordered, while TyrL94 has partial
occupancy to accommodate alternate conformations
of TrpH47.Table 3. Protein-Ligand Interactions in Antibody 7A1
Data Set Apo Cocaine
Transition
State Analog
Two
Productsa
Ecgonine
Methyl Ester
Benzoic
Acid
Heptaethylene
Glycol
van der Waals contacts n/a 74 98 79 43 25 57
H bonding n/a 1 3 2 0 1 1
Volume of combining site (A˚3) w500 w480 w320 w410 w400 w440 w370
Shape correlation (Sc) n/a 0.89 0.87 0.81 0.84 0.76 0.73
a The two products are ecgonine methyl ester and benzoic acid.
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Antibody 7A1 was raised against hapten 5, which is
a transition state analog containing a linker for covalent
attachment to keyhole limpet hemocyanin for immuniza-
tion. Several esterolytic antibodies have been raised
against phosphonate haptens that mimic the putative
tetrahedral transition state of the hydrolytic reaction. In
the 7A1 Fab0 TSA complex (Figure 3C), the overall loca-
tion and orientation of the tropane and methyl ester of
the TSA with respect to the Fab0 is similar to that seen
in the 7A1 cocaine complex, with 90% of its accessible
surface being buried (Figure 4C) and high shape com-
plementarity with an Sc of 0.87 (Table 3). As in the co-
caine complex, an intramolecular hydrogen bond is
formed between the tropane nitrogen atom and the car-
bonyl oxygen of the methyl ester, as well as a bifurcated
hydrogen bond between the tropane nitrogen atom and
the PheL91 carbonyl oxygen.
The contribution to catalysis of the differential stabili-
zation of the transition state relative to substrate can be
analyzed by comparing the 7A1 Fab0 interactions with
the scissile carbonyl in the substrate versus the charged
tetrahedral phosphonate in the TSA, as well as from the
relative disposition of the tropane skeleton-methyl ester
and phenyl ring moieties in both ligands. The tropane-
methyl ester moiety of the TSA makes tight interactions
with the same nine residues of the combining site in both
structures, except for TyrL94, which adopts a different
side chain rotamer that leads to a slight translocation
of the tropane moiety by about 0.8 A˚ toward the center
of the combining site. However, the phenyl ring changes
dramatically from the substrate to TSA so as to stack be-
tween CDRs H3 and H1, H2. In the TSA complex, the
phenyl ring interacts with TyrH97, AspH96, AlaH34,
TyrH50, and ArgH52. The negatively charged pro-R
phosphonyl oxygen of the TSA is within hydrogen bond-
ing distance of TyrL94 (2.5 A˚) and TyrH50 (2.6 A˚), which
both can act as hydrogen bond donors, while the pro-S
oxygen points out toward solvent. We, therefore, pro-
pose that TyrL94 and TyrH50 constitute the oxyanion
hole in 7A1 to stabilize the transition state.
The 7A1 Fab0 structures in the substrate and TSA com-
plexes superimpose with an rmsd of Ca atoms of 0.64 A˚.
For the CDR loops, the most significant backbone shift is
observed around ArgH52–ArgH58 (rmsd of 1.5 A˚ for Ca
atoms) of CDR H2, and the largest movement (w2.3 A˚)
is seen for the Ca atom of ValH55. A small change occurs
around LeuL27C–TyrL32 (rmsd of 0.6 A˚ for Ca atoms) of
CDR L1. However, the most significant conformational
changes occur for several active site residues that adopt
different combinations of side chain rotamers and main
chain movements; TyrL94 OH differs by 6.6 A˚, TyrH50
OH differs by 2.6 A˚, Arg52 Cz differs by 3.4 A˚, and
ArgH58 Czdiffers by 5.4 A˚. The active site compresses on
TSA binding, and the total volume is reduced tow320 A˚3
compared to 480 A˚3 in the cocaine complex (Table 3, cal-
culated with GRASP [Nicholls et al., 1991]), mainly due to
movement of CDRs H2 and L1 and side chain rotations of
the aforementioned residues (Figures 4B and 4C).
Interactions of the Two Reaction Products
with the Active Site
High concentrations of both products, ecgonine methyl
ester (3.8 mM) and benzoic acid (3.8 mM), were used inthe cocrystallization with 7A1 Fab0. Clear electron den-
sity (Figure 3D) was apparent for both ligands that are
both 86% buried in the active site (Figure 4D). The ecgo-
nine methyl ester superposes within experimental error
(rmsd of 0.2 A˚) with the corresponding moiety of the TSA
(Figure 3C) and makes similar hydrogen bonds, cation-p
interactions, and van der Waals’ interactions; however,
TyrL94 shows yet another side chain rotamer and partial
occupancy. The benzoic acid rotates significantly com-
pared to the benzoyl moiety of the TSA; thus, its car-
boxyl group points toward the solvent (Figure 3D). The
benzoate carboxylate is almost parallel to the ArgH52
guanidinium, with a distance of about 3.8 A˚, and it con-
tributes to electrostatic interactions. The benzoic acid
interacts with AsnH32, AlaH34, ArgH52, AspH96, and
TyrH97 (21 van der Waals’ contacts, one H bond with
AsnH32), but not with TyrH50 as in the TSA complex.
For the CDR loops, slight backbone shifts (Figures 3C
and 3D) again arise around ArgH52–ArgH58 (rmsd of
0.6 A˚ for Ca atoms) of CDR H2, LeuL27C–TyrL32 (rmsd
of 0.4 A˚) of CDR L1, and PheL91–ProL95 (rmsd of 0.9
A˚) of CDR L3. For active site residues, TyrL94 OH shifts
by 8.7 A˚, TyrH50 OH shifts by 1.3 A˚, ArgH52 Cz shifts by
2.2 A˚, and ArgH58 Cz shifts by 4.8 A˚ due to different side
chain rotamers coupled to main chain movements. The
resulting active site volume is w410 A˚3, which is larger
than the TSA complex (w320 A˚3), but smaller than the
cocaine complex (w480 A˚3) (Table 3).
Interactions of Product Ecgonine Methyl Ester
with the Active Site
As expected, the crystal structures of 7A1 Fab0 in com-
plex with ecgonine methyl ester (Figure 3E) is very sim-
ilar to its complex with both products (Figure 3D), with
rms deviations for Fv equivalent Ca atoms of 0.4 A˚, ex-
cluding the first 12 residues of the light chain (0.65 A˚
for residues 1–105 in both chains). Intriguingly, 7A1
Fab0 in complex with ecgonine methyl ester (Figure 3E)
also superimposes closely with the TSA structure
(Figure 3C) with an rmsd of 0.44 A˚ (Fv Ca), and the ecgo-
nine methyl ester makes similar contacts to the Fab0 with
7 van der Waals’ interactions with TyrH97 and 36 van der
Waals’ interactions with VL. No hydrogen bonds are
formed, as the tropane nitrogen atom is 3.8 A˚ from the
carbonyl oxygen of PheL91; however, cation-p inter-
actions are still made with TyrL27D and TyrL32. The
CDR loop conformations are similar to those of the
two-product complexes, as well as the active site resi-
due rotamers, except, again, for TyrL94 and ArgH58,
which rotate toward their conformation in the TSA com-
plex. In this case, these two side chains might be influ-
enced by crystal packing, as symmetry-related residues
H162–H165 would collide with these residues if they
adopted the same conformation in the two-product
complex. Hence, TyrH94 is fully occupied and makes
additional van der Waals’ interactions with the methyl
ester of the ligand.
Interactions of Product Benzoic Acid
with the Active Site
The benzoic acid complex structure (Figure 3F) is also
similar to that of the two-product complex, with an
rmsd of 0.22 A˚ (Fv Ca). No significant conformational
changes were observed, except for a slight shift of
Snapshots of a Cocaine Antibody Catalytic Cycle
211CDR L3 (ValL92–PheL96, rmsd of 0.7 A˚ for Ca atoms).
The benzoic acid occupies a similar position and makes
25 van der Waals’ contacts with AsnH32, TyrH33,
AlaH34, ArgH52, and TyrH97, and it makes 1 hydrogen
bond with AsnH32 (Table 3). As with the two-product
complex, the guanidinium of ArgH52 is almost parallel
to the carboxylate group of benzoic acid at a distance
of 3.8 A˚, contributing to an electrostatic interaction. It
is noteworthy that most active site residues retain the
same side chain rotamers as in the two-product struc-
ture, except for TyrL94 which continues to be flexible. In-
terestingly, TyrL27D is now disordered compared to the
other 7A1 Fab0 structures.
Discussion
Conformational Changes along the Reaction
Coordinate
Understanding the molecular mechanism of protein ca-
talysis and allosteric regulation has been a key focus of
modern biochemistry and structural biology. The impor-
tance of isomerism and induced fit in enzyme catalysis
has long been recognized; thus, protein flexibility is
now known to be an essential characteristic of most en-
zymes. It is commonly accepted that, in most enzymes,
the ‘‘open’’ form of an enzyme initially binds the sub-
strate, and then closes around the substrate in the
‘‘closed’’ form. Catalysis takes place within the closed
form, after which the enzyme including the active site
loops opens to release the product. The catalytic and
binding residues are often amongst the most flexible
parts of the structure, although the overall structure
may not change significantly; in some cases, large do-
main rearrangements are observed in multidomain pro-
teins upon substrate binding (Gutteridge and Thornton,
2004).
Ideally, enzyme mechanistic studies should include
experimentally determined structures of all of the steps
along the reaction coordinate, but that is rarely possible
in practice. This series of crystal structures of antibody
7A1 has provided snapshots for each of the six steps
along the reaction coordinates (Figures 3 and 4). Signif-
icant conformational changes of up to 9 A˚, especially for
key residues, occur along the 7A1-catalyzed cocaine hy-
drolysis pathway and play a critical role in the catalytic
reaction. In the unliganded apo structure, the active
site adopts an ‘‘open’’ form, in which the side chains of
two key residues, TyrL94 and TyrH97, are highly flexible
(Figure 3A). When the antibody binds cocaine, the active
site still retains a modified ‘‘open’’ form, in which TyrH97
now becomes fixed, TyrL94 displays some partial stabi-
lization, and TrpH47 populates two side chain rotamers
(Figure 3B). In the transition state, the active site adopts
the ‘‘closed’’ form, in which the CDR loops, particularly
H2, progress toward the active site (Figure 3C). TyrL94
and TyrH50 now rotate and shift to make hydrogen
bonds with the pro-R phosphonate oxygen, and they
generate an oxyanion hole to stabilize the transition
state. The side chains of ArgH52, ArgH58, and IleH56 re-
position themselves by several angstroms, thus contrib-
uting toward TSA sequestration within the active site
that stabilizes the oxyanion intermediate more efficiently
than the substrate. When cocaine hydrolysis is com-
pleted, the two products initially remain trapped in theactive site that now returns to an intermediate ‘‘open’’
form; the side chains of TyrH50, ArgH52, ArgH58, and
IleH56 adopt conformations between those found in
the transition state and those in the substrate bound
state, and the side chain of TyrL94 shows partial occu-
pancy and a different rotamer (Figure 3D).
Protein conformational changes among different
states of a catalytic reaction can be categorized into
four different types of motions: side chain rotamer
changes, loop movements, secondary structure
changes, and domain motions (Gutteridge and Thorn-
ton, 2004). These changes enhance binding of sub-
strate, optimally orientate the catalytic groups, remove
water from the active site (except if catalytic), and trap
and stabilize intermediates. In 7A1, only loop move-
ments and side chain motions appear to play dominant
roles in the cocaine hydrolysis reaction, but these alter
the binding pocket volumes considerably (from w320
to 500 A˚3) (Table 3). However, other small motions could
still be important for catalysis, as residue movements of
less than 1 A˚ can alter the rate of catalysis by several or-
ders of magnitude (Koshland, 1998). Although static
snapshots given by X-ray crystallography do not com-
pletely reveal the entire dynamics of the catalytic pro-
cess, these crystal structures represent a clear view of
the enzyme state at each stage in the reaction cycle.
The conformational flexibility of the 7A1 active site is
further confirmed by the crystal structure of 7A1 com-
plexed with heptaethylene glycol (Figure 5) from the
crystallization solution. The active site pocket (Figure 5)
is similar in size to that of the two-product complex
(Figure 3E), in which TyrH50, ArgH58, ArgH52, and
IleH56 superimpose well within experimental error, but
TyrL94 and TyrH97 are fixed in rotamers not observed
in the other 7A1 Fab0 structures. TyrL94 now points
away from the active site center, while TyrH97 flips
into the pocket that benzoic acid occupied in the prod-
uct complexes, and its side chain hydroxyl oxygen forms
a hydrogen bond with the carboxamide of AsnH32. To
our knowledge, the binding of heptaethylene glycol
to an antibody-combining site has not been reported
before, although, here, it does not show any obvious in-
hibition of the 7A1 catalytic reaction.
Catalytic Mechanism
Direct hydroxide attack on the scissile carbonyl of the
substrate is a likely mechanism for antibody-catalyzed
esterolytic reactions and has been confirmed in crystal
structures of esterolytic antibodies that were elicited
by phosphonate haptens that mimic the transition states
of the reaction (MacBeath and Hilvert, 1996). The mech-
anism of nonenzymatic hydrolysis of cocaine has been
explored (Zhan and Landry, 2001), and calculations on
methyl and benzoyl ester hydrolysis suggest that forma-
tion of a tetrahedral intermediate via hydroxide attack on
the carbonyl carbon is the rate-determining step. In the
7A1-cocaine structure (Figure 3B), all residues that
could potentially promote nucleophilic or general base
catalysis are more than 6 A˚ away from the scissile
bond. However, in the 7A1-TSA structure (Figure 3C),
the side chains of TyrL94 and TyrH50 reorient to form hy-
drogen bonds with the pro-R phosphonate oxygen of
the TSA (Figure 6). All of these observations suggest
that oxyanion stabilization plays a major role in the
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212Figure 5. The Combining Site of the Antibody
7A1 in Complex with Heptaethylene Glycol
(A) Stereoview of the active site of 7A1 with
bound heptaethylene glycol.
(B) Shape complementarity of heptaethylene
glycol in the 7A1 combining site. The molecu-
lar surface is colored by electrostatic potential
(calculated with GRASP [Nicholls et al., 1991]
with a 1.4 A˚ probe radius and contoured be-
tween 230 to +30 kT).catalysis, in which a solvent water molecule or hydrox-
ide ion could attack the scissile carbonyl of the benzoyl
ester and the antibody provides stabilization for the an-
ionic transition state. Attack could be initiated from one
side of the re- or si-face of the carbonyl group. Examina-
tion of the 7A1 crystal structures of the apo form, sub-strate, TSA, and product complexes (Figure 3) reveals
that several water molecules are located in the active
site, although none are positioned within contact dis-
tance (<3.9 A˚ away) of the pro-R or pro-S phosphonate
oxygen atoms in the TSA complex, or of the scissile car-
bonyl in the cocaine complex. One conserved waterFigure 6. Proposed Mechanism for the 7A1-
Catalyzed Cocaine Hydrolysis Reaction
The hydrogen bonds and cation-p interac-
tions are shown in dotted lines (see the text
for details). 1, apo form; 2, substrate bound
state; 3, transition state; 4, two-product
bound state; 5, ecgonine methyl ester bound
state; 6, benzoic acid bound state. The flexi-
ble residues TyrL94, TyrH97 in 1, and
TyrL94 and TyrL27D in 6 are omitted.
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213molecule, S1, is buried deep within the active site pocket
and hydrogen bonds to TrpH47 N31, except in the co-
caine complex (Figure 3). This water molecule is 6–8 A˚
from the scissile carbonyl of cocaine or the phospho-
nate oxygen atoms of the TSA. However, analysis of
the distribution of water molecules in the active sites
of all of the structures shows some clustering on the
re-face of cocaine on which TyrL94 and TyrH50 also re-
side. Furthermore, after superimposing the tropane-
methyl ester moieties of the cocaine and TSA com-
plexes, the benzoyl carbonyl oxygen of the cocaine al-
most overlaps with the pro-S oxygen of the TSA. Since
the si-face around the benzoyl ester carbonyl group of
the substrate cocaine is partially buried in the active
site, all of these analyses indicate that the hydroxide
ion could attack from the re-face. The intimate hydrogen
bonds formed by TyrL94 (2.5 A˚) and TyrH50 (2.6 A˚) to the
pro-R phosphonate oxygen of the transition state ana-
log further suggest that these residues play an important
role in stabilizing the developing negative charge on the
transition state. In esterolytic antibody 7C8, only one ty-
rosine makes a hydrogen bond to its TSA (Gigant et al.,
1997). In 7A1, the nucleophile must be a hydroxide ion or
a water molecule, and TyrL94 and TyrH50 are hydrogen
bond donors (Figure 6). The catalytic rate of 7A1 should
then be a function of both hydroxide ion concentration
and of the percentage of tyrosines that are in the proton-
ated state. Once the hydrolytic reaction is achieved,
both products would diffuse quickly into solvent, since
no obvious product inhibition is observed in the kinetic
experiments. Because the tropane and benzoic acid
moieties are buried in such shallow slots in the combin-
ing site, each product of cocaine hydrolysis would no
longer possess sufficient binding affinity to provide
any observable product inhibition.
Comparison to Other Relevant Structures
To date, antibody 15A10 is the only other cocaine hydro-
lytic antibody with a reported crystal structure, although
only in its apo form (Larsen et al., 2004). Comparison of
antibody 7A1 with 15A10 reveals several significant dif-
ferences. These two antibodies share only 33% identity
in the light chain sequence and 44% identity in the
heavy chain sequence (data not shown). At a structural
level, the overall shape of the binding pocket of 15A10
is strikingly different from that of 7A1 due mainly to the
different conformation of the CDR L3 and H3 loops, as
well as the different side chain conformation of key res-
idues; the binding pocket of 15A10 is also much deeper
than that of 7A1. Although a crystal structure of 15A10
in complex with its TSA is not available, computational
docking of a TSA into the published native crystal
structure has led to a plausible binding model, which
correlates well with results from site-directed mutagen-
esis and chemical modification (Larsen et al., 2004).
The proposed model supports the notion that AsnH33,
TyrH35, and TrpL96 donate four hydrogen bonds to the
two phosphonate oxygens of the TSA to stabilize the
transition state of the cocaine hydrolysis reaction. In
antibody 7A1, TyrL94 and TyrH50 donate two hydrogen
bonds to only one of the phosphonate oxygens of
the TSA. Although there is no apparent electrostatic
complementarity in the binding pocket of 15A10, two
additional hydrogen bonds might contribute to stron-ger oxyanion stabilization and account for its higher
rate enhancement (kcat of 2.3 min
21, KM of 220 mM,
and kcatkuncat
21 of 23,000 measured in 50 mM PB at
pH 7.8 [Yang et al., 1996]) compared to 7A1 (kcat of
0.025 min21, KM of 750 mM, and kcatkuncat
21 of 2,630
measured in 100 mM PB at pH 7.4).
Crystal structures of seven other families of hydrolytic
antibodies have been determined, including 17E8 (Zhou
et al., 1994), CNJ206 (Charbonnier et al., 1995), D2.3
(Charbonnier et al., 1997), 48G7 (Wedemayer et al.,
1997), 6D9 (Kristensen et al., 1998), 43C9 (Thayer et al.,
1999), and MS6-12 (Ruzheinikov et al., 2003), which
were raised against an aryl or benzyl phosphonate or
phosphonamidate TSA and catalyze the hydrolysis of
arylesters and amides. As summarized previously (Goli-
nelli-Pimpaneau, 2002; Larsen et al., 2004), crystal struc-
tures of esterolytic catalytic antibodies have revealed
obvious similarities in their TSA binding mode and in
the oxyanion hole. Hydrogen bond-donating residues
recognize the anionic phosphonate oxygens, and their
aromatic moieties are sequestered in a hydrophobic
pocket. In these antibodies, the hapten aryl group is
buried deep within the binding pocket, which is not the
case for the cocaine tropane skeleton in 7A1. Except
for 6D9 and 7C8, the combining sites of the hydrolytic
antibodies elicited against similar haptens also result
in similar residues, such as HisH35, Tyr or Arg at L96,
and residues at positions H100, H33, or H95, making
more than three hydrogen bonds to the two oxygens
of the hapten. For antibody 7A1, the hydrogen bond
donors are two tyrosine residues, TyrH50 and TyrL94,
which form two hydrogen bonds with only one of the
hapten phosphonate oxygens. Based on our crystallo-
graphic analysis, site-directed mutagenesis of antibody
7A1 may now be carried out with a high degree of confi-
dence to increase the number of hydrogen bonds with
the transition state so as to stabilize the developing neg-
ative charge.
In conclusion, immunopharmacotherapy for cocaine
addiction has been demonstrated to be a feasible
treatment strategy for cocaine abuse. Cocaine de-
grades in vivo through modest hydrolysis and enzy-
matic degradation by liver carboxylesterase and serum
butyrylcholinesterase; cocaine has an in vivo half-life
of w30 min. Hence, an effective cocaine catalytic anti-
body must out-compete these natural processes to di-
minish the psychoactive consequences of the drug. To
achieve this goal of enzyme-like efficiency, it may be
necessary to explore new approaches for eliciting
and optimizing such catalytic activity. New functional
groups could be introduced into the first-generation
antibody catalysts by site-directed mutagenesis to cir-
cumvent the low probability of obtaining the required
complex constellation of catalytic residues in a single
step in the immunization process. An incremental ap-
proach will probably be required in which modest cat-
alysts are improved by multiple rounds of mutagenesis
and selection (MacBeath and Hilvert, 1996). These
crystal structures of 7A1 now provide a foundation for
antibody humanization and mutagenesis studies to en-
hance its cocaine catalytic activity. For 7A1, two key
residues, TyrH50 and TyrL94, appear to stabilize the
transition state, in contrast with other catalytic anti-
bodies, such as CNJ206 and 17E8 (MacBeath and
Structure
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bilize the transition state. Replacement of TyrH50 and
TyrL94 by lysine or arginine may improve catalytic ac-
tivity. For 7A1, ArgH52, IleH56, ArgH58, and TyrH97
also undergo large conformational changes (up to 6 A˚)
in the catalytic process; thus, their relative contributions
to catalysis should be further explored. An esterase
antibody has been successfully evolved through selec-
tion of second shell residues, outside of the active site,
which stabilize the active site structure (Arkin and Wells,
1998); hence, mutagenesis of second shell residues and
screening by phage display could be another strategy
(Arkin and Wells, 1998; Gao et al., 1997; Janda et al.,
1997).
Structural dynamics are now included in the determi-
nation of the mechanism of action of many proteins. For
enzymes, it is generally difficult to identify the key con-
formational changes in the reaction processes, as they
are usually much faster than the chemical step and
product release (Fersht, 1985). Conformational changes
in antibodies have been examined by structural
methods, but the available structural data have focused
mainly on interactions with TSAs, which have confirmed
the shape or chemical complementarity between the
binding pocket and the haptenic TSA. The esterase-
like antibody, D2.3, is the only other example for which
crystal structures have been determined in complex
with a substrate analog, TSA, or one of the reaction
products. However, in this case, significant structural
differences were not observed along the reaction path-
way (Gigant et al., 1997), although extensive kinetic
studies suggested the importance of conformational
changes (Lindner et al., 1999). Thus, this comprehensive
study of high-resolution crystal structures of antibody
7A1, in the apo form, substrate complex, TSA complex,
and products complexes, have shed light on the se-
quence of events from substrate to products in an anti-
body-mediated reaction, and it provides a rare snapshot
of structural dynamics that can occur in antibody and
enzyme catalysis.
Experimental Procedures
Kinetic and Inhibition Measurements
Murine monoclonal antibody 7A1 was elicited against hapten GNL 5
(Figure 1) coupled to keyhole limpet hemocyanin (KLH) as previously
described (Matsushita et al., 2001). The initial rates of 7A1-catalyzed
degradation of cocaine were determined by monitoring the forma-
tion of benzoic acid by analytical reversed-phase HPLC (RP-HPLC)
and were quantified at 254 nm (Hitachi L-7200; Vydac 201TP54
C-18 column; isocratic mobile phase of 17% MeCN, 83% H2O [0.1%
TFA]; flow rate 1 ml/min). The retention times for benzoic acid, ben-
zoylecgonine, and cocaine were 10 min, 7.5 min, and 13 min, respec-
tively. Benzoic acid concentrations were determined by interpolation
of peak height and area values relative to standard curves. Unless
otherwise noted, all reactions were performed in 100 mM MOPS
(pH 7.4), and all of the experiments were performed in triplicate.
The dependence of the cocaine hydrolysis rate on pH was deter-
mined by the measurement of the Vmax of 7A1 in 100 mM MOPS at
pH 6.4, 7.1, 7.4, 8.0, and 8.5. In all cases, reactions were prepared
by mixing antibody (20 mM) and cocaine (2.8 mM) at 23ºC. Every
200 min, an aliquot was removed from the reactions and analyzed
by RP-HPLC by using the described separation conditions.
For the study of the inhibition of 7A1 by ecgonine methyl ester,
a solution was prepared containing antibody (20 mM), cocaine
(0.5–4.0 mM), and ecgonine methyl ester (0–3.7 mM). After several
hours of incubation at 23ºC, an aliquot was removed and analyzedfor benzoic acid formation by RP-HPLC by using the described
separation conditions. In order to assess the inhibition of 7A1 by
benzoic acid or heptaethylene glycol, reactions were prepared con-
taining antibody (20 mM), cocaine (2.8 mM), and benzoic acid or
heptaethylene glycol (1 mM). The rate of benzoic acid formation
was compared to that of control reactions containing antibody
(20 mM) and cocaine (2.8 mM) alone. Further control samples con-
taining benzoic acid (100 mM–10 mM) were also analyzed. In all
cases, after several hours of incubation, an aliquot was removed
and analyzed by RP-HPLC by using the described separation
conditions.
Fab0 Preparation and Purification
The Fab0 fragment of 7A1 was produced by standard protocols
(Harlow and Lane, 1998). The intact 7A1 IgG was digested to
(Fab0)2 with 2% (w/w) pepsin for 4 hr and was followed by reduction
to Fab0 by 20 mM 2-mercaptoethylamine (MEA) for 4 hr. The protein
was purified to homogeneity by a combination of protein A and pro-
tein G affinity chromatography, as well as by ion-exchange chroma-
tography (Mono-Q column, Pharmacia) and gel filtration (Super-200
column, Pharmacia).
Crystallization Conditions
7A1 Fab0 was concentrated to 10.7 mg/ml in 0.1 M sodium acetate
(pH 5.5). Crystallization experiments were performed by using the
sitting-drop, vapor diffusion method at 295K (1 ml reservoir solution
and 1 ml protein solution). Apo crystals were grown from 0.1 M so-
dium acetate (pH 5.5), 0.2 M ammonium sulfate, 9.5 mM flavin ade-
nine dinucleotide (FAD), and 20% (w/v) polyethylene glycol (PEG)
4000. For the substrate cocaine complex, 7A1 Fab0 was mixed
with 7.7 mM cocaine-HCl immediately prior to crystallization from
0.1 M sodium acetate (pH 5.5), 0.2 M ammonium formate, and
20% (w/v) PEG 4000. 7A1 Fab0 and TSA were cocrystallized from
0.1 M sodium acetate (pH 5.5), 0.2 M ammonium fluoride, and 20%
(w/v) PEG 4000 with 5.0 mM TSA. 7A1 Fab0 was incubated with
3.8 mM ecgonine methyl ester, 3.8 mM benzoic acid, and the two-
product cocrystals were grown from 0.1 M sodium acetate (pH 5.5),
0.2 M zinc acetate, and 20% (w/v) PEG 4000. 7A1 Fab0 and the prod-
uct ecgonine methyl ester were cocrystallized from 0.1 M sodium
acetate (pH 5.5), 0.2 M ammonium fluoride, and 20% (w/v) PEG
4000 with 7.7 mM ecgonine methyl ester. 7A1 Fab0 was incubated
with 25 mM benzoic acid, and the product benzoic acid cocrystals
were grown from 0.1 M sodium acetate (pH 5.5), 0.2 M zinc acetate,
and 20% (w/v) PEG 4000. 7A1 Fab0 and heptaethylene glycol cocrys-
tals arose from 0.1 M HEPES (pH 7.5), 2% (w/v) PEG 4000, and 2.0 M
ammonium sulfate.
Data Collection and Processing
Crystals of apo 7A1 Fab0 and its other complexes were flash-cooled
in liquid nitrogen with 20%–25% (v/v) glycerol as cryoprotectant.
Data sets were collected at the Advance Light Source (ALS) beam-
line 8.3.1 (ADSC Quantum 210 CCD detector) for the apo form 7A1
Fab0 and its complex with ecgonine methyl ester and benzoic acid,
at ALS beamline 8.2.1 (ADSC Quantum 210 CCD detector) for the co-
caine complex, at ALS beamline 5.0.2 (ADSC Quantum 210 CCD de-
tector) for the TSA complex and the ecgonine methyl ester complex,
at ALS beamline 8.2.2 (ADSC Quantum 315 CCD detector) for the
benzoic acid complex, and at the Stanford Synchrotron Radiation
Laboratory (SSRL) beamline 9-2 (ADSC Quantum 4 CCD detector)
for the heptaethylene glycol complex. All of the data sets were inte-
grated and scaled with HKL2000 (Otwinowski and Minor, 1997) (see
Table 2).
Structure Determination and Refinement
The 7A1 Fab0-heptaethylene glycol structure was determined by
molecular replacement with the program AMoRe (Navaza, 1994)
and Fab A5B7 (PDB code: 1CLO) as a search model. The refined
structure was then used for molecular replacement of all other
data sets. Structural refinement of the apo, cocaine, and heptaethyl-
ene glycol Fab0 structures was initiated in CNS (Bru¨nger et al., 1998)
and completed with REFMAC5 (Murshudov et al., 1999). Anisotropic
B value refinement and alternate conformations for some side chains
were implemented for the apo and cocaine complexes. The TSA
complex and all product complexes were refined in CNS (Bru¨nger
Snapshots of a Cocaine Antibody Catalytic Cycle
215et al., 1998). NCS restraints of 400 kcal/mol and 200 kcal/mol for
main chain and side chain side atoms, respectively, were applied
to the initial refinement of the two-product complex. All ligands
were initially constructed and energy minimized by using InsightII
(ACCELRYS, San Diego, CA). Hydrogen bonds were evaluated
with HBPLUS (McDonald and Thornton, 1994) and CONTACTSYM
(Sheriff et al., 1987), and the electrostatic surface was evaluated
with GRASP (Nicholls et al., 1991). The approximate volume of the
combining site was calculated from the manually scribed molecular
surface in GRASP (Nicholls et al., 1991). Shape complementarity
between antibody and ligands was evaluated by the Sc parameter
calculated with the program SC (Lawrence and Colman, 1993).
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